| # | Title | Journal | Year | Citations |
|---|
| 1 | Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review | Therapeutic Advances in Psychopharmacology | 2013 | 400 |
| 2 | Cannabis, a complex plant: different compounds and different effects on individuals | Therapeutic Advances in Psychopharmacology | 2012 | 357 |
| 3 | Epidemiology and risk factors for bipolar disorder | Therapeutic Advances in Psychopharmacology | 2018 | 285 |
| 4 | The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal | Therapeutic Advances in Psychopharmacology | 2014 | 224 |
| 5 | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years | Therapeutic Advances in Psychopharmacology | 2016 | 204 |
| 6 | Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data | Therapeutic Advances in Psychopharmacology | 2020 | 193 |
| 7 | The drugs don’t work? antidepressants and the current and future pharmacological management of depression | Therapeutic Advances in Psychopharmacology | 2012 | 144 |
| 8 | New psychoactive substances: a review and updates | Therapeutic Advances in Psychopharmacology | 2020 | 141 |
| 9 | Legal highs: staying on top of the flood of novel psychoactive substances | Therapeutic Advances in Psychopharmacology | 2015 | 136 |
| 10 | The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses | Therapeutic Advances in Psychopharmacology | 2018 | 129 |
| 11 | Clozapine-related EEG changes and seizures: dose and plasma-level relationships | Therapeutic Advances in Psychopharmacology | 2011 | 119 |
| 12 | Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant | Therapeutic Advances in Psychopharmacology | 2016 | 119 |
| 13 | Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy | Therapeutic Advances in Psychopharmacology | 2014 | 118 |
| 14 | Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies | Therapeutic Advances in Psychopharmacology | 2017 | 115 |
| 15 | Drug models of schizophrenia | Therapeutic Advances in Psychopharmacology | 2015 | 108 |
| 16 | Medication nonadherence in bipolar disorder: a narrative review | Therapeutic Advances in Psychopharmacology | 2018 | 105 |
| 17 | Lithium: the pharmacodynamic actions of the amazing ion | Therapeutic Advances in Psychopharmacology | 2013 | 103 |
| 18 | Frontotemporal dementia: latest evidence and clinical implications | Therapeutic Advances in Psychopharmacology | 2018 | 102 |
| 19 | Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles | Therapeutic Advances in Psychopharmacology | 2014 | 99 |
| 20 | Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers | Therapeutic Advances in Psychopharmacology | 2020 | 95 |
| 21 | New avenues for treating emotional memory disorders: towards a reconsolidation intervention for posttraumatic stress disorder | Therapeutic Advances in Psychopharmacology | 2016 | 93 |
| 22 | Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole | Therapeutic Advances in Psychopharmacology | 2017 | 91 |
| 23 | The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review | Therapeutic Advances in Psychopharmacology | 2013 | 90 |
| 24 | Plasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma | Therapeutic Advances in Psychopharmacology | 2012 | 82 |
| 25 | Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review | Therapeutic Advances in Psychopharmacology | 2013 | 79 |
| 26 | Lactate in the brain: an update on its relevance to brain energy, neurons, glia and panic disorder | Therapeutic Advances in Psychopharmacology | 2017 | 78 |
| 27 | Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation | Therapeutic Advances in Psychopharmacology | 2018 | 75 |
| 28 | Ketamine enantiomers in the rapid and sustained antidepressant effects | Therapeutic Advances in Psychopharmacology | 2016 | 74 |
| 29 | Cannabidiol as a potential treatment for psychosis | Therapeutic Advances in Psychopharmacology | 2019 | 74 |
| 30 | A review of the management of antidepressant discontinuation symptoms | Therapeutic Advances in Psychopharmacology | 2015 | 71 |
| 31 | Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment | Therapeutic Advances in Psychopharmacology | 2018 | 68 |
| 32 | Genetic risk factors for eating disorders: an update and insights into pathophysiology | Therapeutic Advances in Psychopharmacology | 2019 | 64 |
| 33 | The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder | Therapeutic Advances in Psychopharmacology | 2018 | 55 |
| 34 | Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis | Therapeutic Advances in Psychopharmacology | 2013 | 53 |
| 35 | Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation | Therapeutic Advances in Psychopharmacology | 2014 | 53 |
| 36 | Brexpiprazole: so far so good | Therapeutic Advances in Psychopharmacology | 2016 | 53 |
| 37 | Hallucinogen-persisting perception disorder | Therapeutic Advances in Psychopharmacology | 2012 | 52 |
| 38 | The relationship between nicotine and psychosis | Therapeutic Advances in Psychopharmacology | 2019 | 52 |
| 39 | Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports | Therapeutic Advances in Psychopharmacology | 2014 | 51 |
| 40 | Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia | Therapeutic Advances in Psychopharmacology | 2016 | 51 |
| 41 | Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? | Therapeutic Advances in Psychopharmacology | 2011 | 50 |
| 42 | Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression | Therapeutic Advances in Psychopharmacology | 2018 | 50 |
| 43 | High-dose prazosin for the treatment of post-traumatic stress disorder | Therapeutic Advances in Psychopharmacology | 2014 | 48 |
| 44 | Transdermal patches: the emerging mode of drug delivery system in psychiatry | Therapeutic Advances in Psychopharmacology | 2012 | 47 |
| 45 | Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder | Therapeutic Advances in Psychopharmacology | 2020 | 47 |
| 46 | Clozapine prescribing in the UK: views and experience of consultant psychiatrists | Therapeutic Advances in Psychopharmacology | 2015 | 46 |
| 47 | Assessment and management of sexual dysfunction in the context of depression | Therapeutic Advances in Psychopharmacology | 2018 | 45 |
| 48 | Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis | Therapeutic Advances in Psychopharmacology | 2019 | 45 |
| 49 | The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders | Therapeutic Advances in Psychopharmacology | 2019 | 44 |
| 50 | Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor | Therapeutic Advances in Psychopharmacology | 2011 | 43 |
